Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers EPURIS (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; LIPOFEN (CIP-FENOFIBRATE), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; CONZIP/DURELA (CIP-TRAMADOL ER), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain; and Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne in patients. It also provides BETEFLAM PATCH, a self-adhesive medicated plaster for the treatment of inflammatory skin conditions; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; and Ozenoxacin to treat adult and paediatric patients with impetigo. In addition, the company has various commercial and pipeline hospital products administered in the acute care setting. Its pipeline products include Dermadexin and Pruridexin for the treatment of common chronic conditions; CF101 for the treatment of plaque psoriasis and rheumatoid arthritis; DTR-001 that is in pre-clinical stage of development for the removal or reduction of the appearance of tattoos; and ASF-1096, an orphan drug indication for the treatment of anorectal indications. Cipher Pharmaceuticals Inc. has a licensing agreement with Synergy Pharmaceuticals Inc. for developing, marketing, distributing, and selling TRULANCE (plecanatide). The company was founded in 2004 and is headquartered in Mississauga, Canada.
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-905-6025840
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Cipher Pharmaceuticals (OTCMKTS:CPHRF) Frequently Asked Questions
What is Cipher Pharmaceuticals' stock symbol?
Cipher Pharmaceuticals trades on the OTCMKTS under the ticker symbol "CPHRF."
How were Cipher Pharmaceuticals' earnings last quarter?
Cipher Pharmaceuticals Inc (OTCMKTS:CPHRF) announced its quarterly earnings data on Thursday, May, 5th. The company reported ($0.10) EPS for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.06. The firm earned $9.10 million during the quarter, compared to analyst estimates of $10.87 million. View Cipher Pharmaceuticals' Earnings History.
Has Cipher Pharmaceuticals been receiving favorable news coverage?
Press coverage about CPHRF stock has been trending somewhat positive recently, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cipher Pharmaceuticals earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Cipher Pharmaceuticals.
Who are some of Cipher Pharmaceuticals' key competitors?
Some companies that are related to Cipher Pharmaceuticals include 1933 Industries (TGIF), Abacus Health Products (ABAHF), Acreage (ACRGF), Alliance Growers (ACG), Applied Biosciences (APPB), Biome Grow (BIO), Blueberries Medical (BBM), Cannabis Science (CBIS), Cannara Biotech (LOVE), Cansortium (CNTMF), Charlotte's Web (CWBHF), Choom (CHOOF), CLS Holdings USA (CLSH), Cosmos (COSM) and Curaleaf (CURLF).
What other stocks do shareholders of Cipher Pharmaceuticals own?
Who are Cipher Pharmaceuticals' key executives?
Cipher Pharmaceuticals' management team includes the folowing people:
- Mr. Robert D. Tessarolo, Pres, CEO & Director (Age 51)
- Mr. Stephen L. Lemieux, CFO & Sec.
- Mr. Chris Watters, VP of Corp. Devel.
- Dr. Diane Gajewczyk, VP of Scientific & Medical Affairs
- Mr. Norman Evans, Consultant (Age 64)
How do I buy shares of Cipher Pharmaceuticals?
Shares of CPHRF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cipher Pharmaceuticals' stock price today?
One share of CPHRF stock can currently be purchased for approximately $0.92.
What is Cipher Pharmaceuticals' official website?
How can I contact Cipher Pharmaceuticals?
Cipher Pharmaceuticals' mailing address is 2345 Argentia Rd Suite 100A, MISSISSAUGA, ON L5N 8K4, Canada. The company can be reached via phone at +1-905-6025840.
MarketBeat Community Rating for Cipher Pharmaceuticals (OTCMKTS CPHRF)
MarketBeat's community ratings are surveys of what our community members think about Cipher Pharmaceuticals and other stocks. Vote "Outperform" if you believe CPHRF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPHRF will underperform the S&P 500 over the long term. You may vote once every thirty days.
